ArticleEmerging infectious diseases2017
Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium.
Article in Emerging infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa.The Journal of antimicrobial chemotherapy · 2022Pooled it
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Spread of dual-class drug-resistantAntimicrobial agents and chemotherapy · 2026Article
- Mathematical analysis of Mycoplasma Genitalium transmission dynamics: A compartmental model with nonlinear interactions and treatment effects.PLOS global public health · 2026Article
- Frequency of macrolide resistance-associated mutations in Mycoplasma genitalium: a multicenter molecular analysis based in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Exploring the pangenome of Mycoplasma hyorhinis in search of potential virulence markers.Scientific reports · 2025Article
- Comparative Study of the Clinical Characteristics of Patients With Sexually Transmitted Infections Diagnosed by Nucleic Acid Amplification Tests.Journal of Korean medical science · 2025Article
- Mycoplasma Genitalium - Where are we at?Current HIV/AIDS reports · 2025Review
- In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin.The Journal of antimicrobial chemotherapy · 2025Article
- Development of a New Rapid Simultaneous Molecular Assay for the Detection of STI Pathogens and Drug Resistance-Associated Mutations.Molecular diagnosis & therapy · 2025Article
- Chinese advances in understanding and managing genitourinary tract infections caused by Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum.Archives of microbiology · 2024Review
- Prevalence and Risk Factors for Antimicrobial Resistance ofJournal of clinical medicine · 2024Article
- Identification of phytochemical inhibitors targeting phosphate acetyltransferase of Mycoplasma genitalium: insights from virtual screening and molecular dynamics studies.Molecular diversity · 2024Article
- Article
- 2023 Korean sexually transmitted infections treatment guidelines forInvestigative and clinical urology · 2024Review
- Etiological, sociodemographic and clinical characteristics of sexually transmitted infections andFrontiers in cellular and infection microbiology · 2024Article
- Article
- Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.JMIR research protocols · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure. Combined macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.